---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-010101"
form_type: "8-K"
ticker: "LUCD"
cik: "0001799011"
company_name: "Lucid Diagnostics Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T09:47:27.016772+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lucid Diagnostics Q1 2025 revenue $0.8M, net loss $36M; raises ~$46.7M in equity

## Summary
- Revenue of $0.8M from 3,034 EsoGuard tests; GAAP net loss $36.0M ($0.52/share); adjusted loss $11.2M ($0.16/share).
- Ended Q1 with $25.2M cash; subsequent public offering netted $16.1M; combined with earlier offerings total ~$46.7M raised.
- Partnered with major health system for EsoGuard testing; NCI study supports expanded indication without GERD, increasing market 70%.
- Cash-pay and employer channels expected to start contractually-guaranteed revenue in 2H25.
- Proforma cash over $40M at Q1 end; runway extended past key Medicare and other reimbursement milestones.

## SEC filing metadata
- accession: 0001641172-25-010101
- form_type: 8-K
- ticker: LUCD
- cik: 0001799011
- company_name: Lucid Diagnostics Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799011/000164117225010101/0001641172-25-010101-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799011/000164117225010101/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-010101
- JSON: https://secwatch.observer/filing/0001641172-25-010101.json
- Plain text: https://secwatch.observer/filing/0001641172-25-010101.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.